Collegium Pharmaceutical Inc/ US19459J1043 /
2024-03-28 9:00:00 PM | Chg. -2.0900 | Volume | Bid9:08:30 PM | Ask9:08:30 PM | High | Low |
---|---|---|---|---|---|---|
38.8200USD | -5.11% | 613,299 Turnover: 18.93 mill. |
38.0000Bid Size: 100 | 39.3900Ask Size: 100 | 40.9500 | 38.5900 |
GlobeNewswire
02-08
Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
GlobeNewswire
2023-10-24
Collegium to Report Third Quarter 2023 Financial Results on November 7, 2023
GlobeNewswire
2023-10-10
Zevra Therapeutics Appoints Neil F. McFarlane as President, Chief Executive Officer and Director
GlobeNewswire
2023-08-24
Collegium Announces Extension of Nucynta Regulatory Exclusivity through July 2026
GlobeNewswire
2022-02-15
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: BioDelivery...
GlobeNewswire
2022-02-14
BIODELIVERY SCIENCES ALERT: Bragar Eagel & Squire, P.C. Investigates Merger of BDSI and Encourages I...
GlobeNewswire
2022-02-14
BDSI Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of BioDelivery Sciences Internatio...
GlobeNewswire
2022-02-10
Collegium to Host Conference Call to Discuss Fourth Quarter and Full-Year 2021 Financial Results
GlobeNewswire
2021-12-28
Collegium Announces Settlement Framework to Resolve Pending Opioid-Related Litigation